Hudson Bay Capital Management LP grew its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 83.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,000 shares of the biopharmaceutical company's stock after purchasing an additional 50,000 shares during the period. Hudson Bay Capital Management LP owned about 0.19% of Agios Pharmaceuticals worth $3,615,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth about $33,000. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth about $53,000. Sterling Capital Management LLC lifted its stake in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares in the last quarter. KBC Group NV lifted its stake in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after acquiring an additional 2,338 shares in the last quarter.
Agios Pharmaceuticals Price Performance
Agios Pharmaceuticals stock traded up $0.92 during mid-day trading on Friday, reaching $29.18. 771,981 shares of the company were exchanged, compared to its average volume of 696,290. The company has a fifty day simple moving average of $28.87 and a 200-day simple moving average of $36.81. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The firm has a market cap of $1.69 billion, a PE ratio of 2.57 and a beta of 0.77.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.
Insider Activity
In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.30% of the company's stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on AGIO. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. Scotiabank reduced their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, May 10th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $56.00.
Check Out Our Latest Stock Analysis on Agios Pharmaceuticals
About Agios Pharmaceuticals
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
